114 related articles for article (PubMed ID: 10195772)
1. Expression of interleukin-2 (IL-2) receptor alpha and CD45RO antigen on T-lymphocytes cultured with measles virus antigens, compared with humoral immunity in measles vaccinees.
Toyoda M; Ihara T; Nakano T; Ito M; Kamiya H
Vaccine; 1999 Mar; 17(11-12):1369-75. PubMed ID: 10195772
[TBL] [Abstract][Full Text] [Related]
2. Expression of interleukin-2 receptor alpha and CD45RO antigen on T lymphocytes cultured with rubella virus antigen, compared with humoral immunity in rubella vaccinees.
Toyoda M; Ihara T; Nakano T; Ito M; Kamiya H
Vaccine; 1999 Apr; 17(15-16):2051-8. PubMed ID: 10217606
[TBL] [Abstract][Full Text] [Related]
3. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
Tischer A; Gerike E
Vaccine; 2000 Jan; 18(14):1382-92. PubMed ID: 10618536
[TBL] [Abstract][Full Text] [Related]
4. Development and durability of measles antigen-specific lymphoproliferative response after MMR vaccination.
Bautista-López N; Ward BJ; Mills E; McCormick D; Martel N; Ratnam S
Vaccine; 2000 Jan; 18(14):1393-401. PubMed ID: 10618537
[TBL] [Abstract][Full Text] [Related]
5. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
Zäch K; Nicoara C; Germann D; Matter L
Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
[TBL] [Abstract][Full Text] [Related]
6. Vaccine-induced measles virus antibodies after two doses of combined measles, mumps and rubella vaccine: a 12-year follow-up in two cohorts.
Davidkin I; Valle M
Vaccine; 1998 Dec; 16(20):2052-7. PubMed ID: 9796064
[TBL] [Abstract][Full Text] [Related]
7. [The development and duration of immunity in children vaccinated against measles with the Edmonston-Zagreb vaccine].
Borcić B; Smerdel S; Abu Eldan J; Kolić J; Ferdebar M; Kordić D; Mohacek N
Lijec Vjesn; 1989; 111(4-5):131-4. PubMed ID: 2770398
[TBL] [Abstract][Full Text] [Related]
8. Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation.
Pauksen K; Duraj V; Ljungman P; Sjölin J; Oberg G; Lönnerholm G; Fridell E; Smedmyr B; Simonsson B
Bone Marrow Transplant; 1992 Jun; 9(6):427-32. PubMed ID: 1628126
[TBL] [Abstract][Full Text] [Related]
9. Serologic response to measles-mumps-rubella vaccine among children with upper respiratory tract infection.
Cilla G; Peña B; Marimón JM; Pérez-Trallero E
Vaccine; 1996 Apr; 14(6):492-4. PubMed ID: 8782345
[TBL] [Abstract][Full Text] [Related]
10. Decline in rates of seropositivity for measles, mumps, and rubella antibodies among previously immunized children treated for acute leukemia.
Feldman S; Andrew M; Norris M; McIntyre B; Iyer R
Clin Infect Dis; 1998 Aug; 27(2):388-90. PubMed ID: 9709893
[TBL] [Abstract][Full Text] [Related]
11. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection.
Dennehy PH; Saracen CL; Peter G
Pediatrics; 1994 Oct; 94(4 Pt 1):514-6. PubMed ID: 7936862
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a combined measles-mumps-rubella-chickenpox vaccine.
Just M; Berger R; Just V
Dev Biol Stand; 1986; 65():85-8. PubMed ID: 3030863
[TBL] [Abstract][Full Text] [Related]
13. Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination. Should we be concerned?
Watada B; Kennedy K; Chan D; Church B; Patriquin M; Shariff F; Evans MF
Can Fam Physician; 1998 Jan; 44():53-5. PubMed ID: 9481462
[No Abstract] [Full Text] [Related]
14. The combination measles, mumps, rubella and varicella vaccine in healthy children.
Arbeter AM; Baker L; Starr SE; Plotkin SA
Dev Biol Stand; 1986; 65():89-93. PubMed ID: 3030864
[TBL] [Abstract][Full Text] [Related]
15. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients.
King SM; Saunders EF; Petric M; Gold R
Bone Marrow Transplant; 1996 Apr; 17(4):633-6. PubMed ID: 8722367
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a two-dose measles, mumps, and rubella vaccination schedule in a cohort of college athletes.
Coté TR; Sivertson D; Horan JM; Lindegren ML; Dwyer DM
Public Health Rep; 1993; 108(4):431-5. PubMed ID: 8341775
[TBL] [Abstract][Full Text] [Related]
17. Measles, mumps, and rubella antibodies in vaccinated Baltimore children.
King JC; Lichenstein R; Feigelman S; Luna C; Permutt TJ; Patel J
Am J Dis Child; 1993 May; 147(5):558-60. PubMed ID: 8488803
[TBL] [Abstract][Full Text] [Related]
18. Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up.
Davidkin I; Valle M; Julkunen I
Vaccine; 1995 Nov; 13(16):1617-22. PubMed ID: 8578851
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children.
Watson BM; Laufer DS; Kuter BJ; Staehle B; White CJ; Starr SE
J Infect Dis; 1996 Mar; 173(3):731-4. PubMed ID: 8627041
[TBL] [Abstract][Full Text] [Related]
20. Duration of rubella immunity induced by two-dose measles, mumps and rubella (MMR) vaccination. A 15-year follow-up in Finland.
Davidkin I; Peltola H; Leinikki P; Valle M
Vaccine; 2000 Jul; 18(27):3106-12. PubMed ID: 10856790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
